Back to search results
NCT03582488

Longitudinal Imaging Biomarkers of Disease Progression in DLB

Enrolling by Invitation
PHASE4Ages 18+InterventionalDiagnostic
Kejal Kantarci
~135 participants
Updated 2026-03-19 on ClinicalTrials.gov
What's tested:18F-Flortaucipir

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of change in 18F-Flortaucipir PET imaging and Pittsburgh compound-B PET imaging
Measured over Will be assessed 3 times annually over at least three years

Conditions

Lewy Body Disease

Explore related trials

Lewy Body Dementia

NCT03582488

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic

    Jacksonville, Floridano site contact published

  • Mayo Clinic

    Rochester, Minnesotano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Kejal Kantarci, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of probable DLB, at least 18 years of age, reliable informant who personally speaks with or sees the participant at least weekly, sufficiently fluent in English, must be willing and able to consent to the protocol and undergo up to 6 visits over 5 years, willing and able to undergo neuropsychological testing and no contraindication to MRI imaging.

Exclusion

Presence of another neurologic disorder which could impact findings, such as multiple sclerosis, brain tumors, etc., unwilling to return for follow-up yearly and undergo neuropsychological testing and MR imaging, if undergoing Tau imaging cannot have QT Prolongation, do not have a reliable informant.

What this trial measures

  • Rate of change in 18F-Flortaucipir PET imaging and Pittsburgh compound-B PET imagingWill be assessed 3 times annually over at least three years

    Cortical 18F-Flortaucipir and Global cortical Pittsburgh compound-B uptake will be measured in each participant over three years